NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported significant clinical and regulatory advancements in the second quarter of 2026, according to a coverage update from Stonegate Capital Partners. The company's lead candidate, NEO100, demonstrated positive Phase 2a results in recurrent brain cancer, while its second program, NEO212, gained clarity on a potential accelerated approval pathway from the FDA.
The Phase 2a trial for NEO100 met its primary endpoint, with a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria using Kaplan-Meier estimation. This result compares favorably against a pre-specified benchmark of 20%, achieving statistical significance with a p-value of 0.0047. Additionally, median overall survival (OS) reached 26.09 months, and the treatment demonstrated a favorable tolerability profile with no major toxicities reported. The survival signal is particularly notable, as current salvage therapies for recurrent brain cancer typically offer only 6 to 9 months of benefit.
These results position NEO100 for a potential registrational program. The company intends to request a Type B meeting with the FDA to discuss the design, endpoints, and approval pathway for a pivotal trial. This meeting will be a critical near-term catalyst, as regulatory alignment is essential for advancing the drug toward commercialization.
In addition to NEO100, NeOnc's second clinical program, NEO212, has gained regulatory momentum. The company received Phase 2 CMC (Chemistry, Manufacturing, and Controls) clearance and FDA feedback indicating a potential accelerated approval pathway. This development broadens the company's pipeline and provides a differentiated second asset.
The investment case for NeOnc is expanding beyond a single trial or asset. NEO100 is also being explored in meningioma and pediatric brain tumors, while NEO212 offers a separate clinical program with its own regulatory progress. This platform breadth increases long-term optionality, although funding remains important as development activities expand.
Financially, the company's results are secondary to the clinical and regulatory milestones. Research and development expenses increased to $2.6 million in the quarter, up from $0.7 million in the same period last year, reflecting the intensified development efforts.
Stonegate Capital Partners, the advisory firm providing the coverage update, highlighted that the readout moves NEO100 into a potential registrational pathway and that the survival signal is the more important takeaway. Confirmation in a randomized study remains the next test for the candidate.
The announcement underscores the progress NeOnc has made in advancing its pipeline for brain cancer treatments. With positive clinical data and regulatory clarity, the company is positioned to move its lead candidates toward later-stage development, potentially offering new options for patients with limited treatment choices.
For more details, the full announcement from Stonegate Capital Partners is available, including additional information on the clinical results and regulatory updates.
